Is ELDN or PURR more profitable?

Hyperliquid Strategies' return on equity of -56.04% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Hyperliquid Strategies N/A -56.04% -52.22%

Which has better valuation & earnings, ELDN or SANA?

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A

Is ELDN or SANA more profitable?

Sana Biotechnology's return on equity of -108.01% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Sana Biotechnology N/A -108.01% -40.68%

Eledon Pharmaceuticals (ELDN) Competitors

$3.92 +0.07 (+1.68%)

As of 11:13 AM Eastern

Compare

ELDN vs. CALT, PURR, COLL, XNCR, and SANA

Should you buy Eledon Pharmaceuticals stock or one of its competitors? MarketBeat compares Eledon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eledon Pharmaceuticals include Calliditas Therapeutics AB (publ) (CALT), Hyperliquid Strategies (PURR), Collegium Pharmaceutical (COLL), Xencor (XNCR), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

How does Eledon Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Eledon Pharmaceuticals currently has a consensus target price of $9.67, indicating a potential upside of 146.28%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Eledon Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eledon Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Eledon Pharmaceuticals' return on equity of -116.97% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Eledon Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Eledon Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Eledon Pharmaceuticals' average media sentiment score of 1.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Very Positive
Calliditas Therapeutics AB (publ)	Neutral

Eledon Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Summary

Eledon Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Hyperliquid Strategies?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Hyperliquid Strategies' return on equity of -56.04% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Eledon Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Eledon Pharmaceuticals currently has a consensus price target of $9.67, suggesting a potential upside of 146.28%. Hyperliquid Strategies has a consensus price target of $12.72, suggesting a potential upside of 69.44%. Given Eledon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Eledon Pharmaceuticals is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Hyperliquid Strategies has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Hyperliquid Strategies	$1M	1,084.10	-$16.01M	-$7.37	N/A

In the previous week, Hyperliquid Strategies had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.89 beat Hyperliquid Strategies' score of 0.65 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Very Positive
Hyperliquid Strategies	Positive

Summary

Hyperliquid Strategies beats Eledon Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Collegium Pharmaceutical?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Collegium Pharmaceutical has a net margin of 9.41% compared to Eledon Pharmaceuticals' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.89 beat Collegium Pharmaceutical's score of 0.75 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Very Positive
Collegium Pharmaceutical	Positive

Eledon Pharmaceuticals currently has a consensus price target of $9.67, suggesting a potential upside of 146.28%. Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 66.01%. Given Eledon Pharmaceuticals' higher possible upside, equities research analysts clearly believe Eledon Pharmaceuticals is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17

Eledon Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Collegium Pharmaceutical	$780.57M	1.44	$62.87M	$2.04	16.98

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats Eledon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Xencor?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Eledon Pharmaceuticals has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Xencor	$125.58M	8.72	-$91.92M	-$2.29	N/A

In the previous week, Xencor had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Xencor and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.89 beat Xencor's score of 0.65 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Very Positive
Xencor	Positive

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Xencor	-177.10%	-28.77%	-20.52%

Eledon Pharmaceuticals currently has a consensus target price of $9.67, indicating a potential upside of 146.28%. Xencor has a consensus target price of $24.25, indicating a potential upside of 64.13%. Given Eledon Pharmaceuticals' higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Eledon Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Xencor has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Summary

Eledon Pharmaceuticals beats Xencor on 9 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Sana Biotechnology?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Sana Biotechnology had 3 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 4 mentions for Sana Biotechnology and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.89 beat Sana Biotechnology's score of 0.47 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Very Positive
Sana Biotechnology	Neutral

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Eledon Pharmaceuticals presently has a consensus price target of $9.67, indicating a potential upside of 146.28%. Sana Biotechnology has a consensus price target of $9.50, indicating a potential upside of 164.99%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sana Biotechnology's return on equity of -108.01% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Sana Biotechnology	N/A	-108.01%	-40.68%

Eledon Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.13, suggesting that its share price is 113% more volatile than the broader market.

Summary

Sana Biotechnology beats Eledon Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Get Eledon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELDN vs. The Competition

Export

Metric	Eledon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$302.66M	$3.64B	$6.74B	$12.51B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-5.09	21.01	26.90	24.39
Price / Sales	N/A	314.09	587.69	117.46
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	2.91	8.50	10.92	6.33
Net Income	-$45.62M	$23.83M	$3.58B	$330.66M
7 Day Performance	-0.13%	-3.45%	-2.25%	-0.84%
1 Month Performance	9.94%	6.33%	3.08%	-0.26%
1 Year Performance	0.38%	48.44%	26.23%	19.99%

Eledon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELDN Eledon Pharmaceuticals	2.0817 of 5 stars	$3.93 +1.7%	$9.67 +146.3%	+12.9%	$302.66M	N/A	N/A	10	Positive News
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
PURR Hyperliquid Strategies	2.4293 of 5 stars	$8.18 -7.3%	$12.72 +55.5%	N/A	$1.18B	$1M	N/A	N/A	Gap Down
COLL Collegium Pharmaceutical	2.6 of 5 stars	$36.42 -2.8%	$57.50 +57.9%	+7.1%	$1.18B	$780.57M	17.85	210	News Coverage
XNCR Xencor	2.2537 of 5 stars	$15.68 +5.3%	$24.25 +54.6%	+69.4%	$1.16B	$125.58M	N/A	280	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELDN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. CALT, PURR, COLL, XNCR, and SANA

How does Eledon Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Summary

How does Eledon Pharmaceuticals compare to Hyperliquid Strategies?

Summary

How does Eledon Pharmaceuticals compare to Collegium Pharmaceutical?

Summary

How does Eledon Pharmaceuticals compare to Xencor?

Summary

How does Eledon Pharmaceuticals compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. CALT, PURR, COLL, XNCR, and SANA

How does Eledon Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Do analysts rate ELDN or CALT?

Is ELDN or CALT more profitable?

Do institutionals & insiders believe in ELDN or CALT?

Which has better earnings and valuation, ELDN or CALT?

Does the media prefer ELDN or CALT?

Which has more risk and volatility, ELDN or CALT?

Summary

How does Eledon Pharmaceuticals compare to Hyperliquid Strategies?

Is ELDN or PURR more profitable?

Which has more volatility & risk, ELDN or PURR?

Do analysts recommend ELDN or PURR?

Do insiders & institutionals believe in ELDN or PURR?

Which has better earnings & valuation, ELDN or PURR?

Does the media prefer ELDN or PURR?

Summary

How does Eledon Pharmaceuticals compare to Collegium Pharmaceutical?

Is ELDN or COLL more profitable?

Does the media refer more to ELDN or COLL?

Do analysts rate ELDN or COLL?

Which has more risk and volatility, ELDN or COLL?

Which has higher earnings & valuation, ELDN or COLL?

Do insiders & institutionals believe in ELDN or COLL?

Summary

How does Eledon Pharmaceuticals compare to Xencor?

Which has stronger earnings & valuation, ELDN or XNCR?

Does the media prefer ELDN or XNCR?

Do institutionals and insiders believe in ELDN or XNCR?

Is ELDN or XNCR more profitable?

Do analysts prefer ELDN or XNCR?

Which has more volatility & risk, ELDN or XNCR?

Summary

How does Eledon Pharmaceuticals compare to Sana Biotechnology?

Do insiders and institutionals believe in ELDN or SANA?

Does the media prefer ELDN or SANA?

Which has better valuation & earnings, ELDN or SANA?

Do analysts prefer ELDN or SANA?

Is ELDN or SANA more profitable?

Which has more volatility and risk, ELDN or SANA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools